Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00239668 · ClinicalTrials.gov registry record

Multicenter Benchmarking of Functional and Psychosocial Outcomes of Pediatric Burn Survivors

A clinical trial, sponsored by Massachusetts General Hospital.

Completed
Registry status
3,000
Enrollment target

NCT00239668: Completed study, sponsored by Massachusetts General Hospital.

NCT00239668 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 3,000 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00239668 has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
3,000 participants
Enrollment target

Study Summary

The purpose of this study is to establish an expected recovery trajectory (recovery model) in terms of physical and psychological function of the pediatric burn patient.

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2000-03
Est. Completion 2013-01
Massachusetts General Hospital

2,032 total trials

What the finished NCT00239668 record still lists

NCT00239668 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT00239668 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00239668 about?

NCT00239668 is a clinical study titled "Multicenter Benchmarking of Functional and Psychosocial Outcomes of Pediatric Burn Survivors". The purpose of this study is to establish an expected recovery trajectory (recovery model) in terms of physical and psychological function of the pediatric burn patient.

What is the current status of trial NCT00239668?

This trial is currently completed. The enrollment target is 3,000 participants. The study started on 2000-03. Estimated completion is 2013-01.

Who is sponsoring clinical trial NCT00239668?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004847 · 3,000 participants · Phase 1

    Diagnosis of Pheochromocytoma

  • NCT00478712 · 3,000 participants

    Hirschsprung Disease Genetic Study

  • NCT00579566 · 3,000 participants

    Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

  • NCT00816114 · 3,000 participants

    Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00239668, the US trial registry maintained by the National Library of Medicine. NCT00239668 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.